Shares of CIGNA Co. (NYSE:CI) have earned a consensus recommendation of “Buy” from the fifteen analysts that are presently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $239.46.

CI has been the subject of several recent research reports. Morgan Stanley initiated coverage on shares of CIGNA in a research report on Thursday. They issued an “overweight” rating and a $304.00 price target for the company. SunTrust Banks increased their price target on shares of CIGNA and gave the stock a “buy” rating in a research report on Thursday, September 27th. Zacks Investment Research lowered shares of CIGNA from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 9th. ValuEngine raised shares of CIGNA from a “sell” rating to a “hold” rating in a research report on Monday, September 17th. Finally, Barclays increased their price target on shares of CIGNA from $228.00 to $235.00 and gave the stock an “overweight” rating in a research report on Friday, November 2nd.

NYSE:CI opened at $205.37 on Tuesday. CIGNA has a 12-month low of $163.02 and a 12-month high of $227.13. The company has a debt-to-equity ratio of 1.61, a current ratio of 0.98 and a quick ratio of 0.98. The stock has a market capitalization of $50.01 billion, a P/E ratio of 19.63, a price-to-earnings-growth ratio of 1.16 and a beta of 0.54.

CIGNA (NYSE:CI) last posted its quarterly earnings results on Thursday, November 1st. The health services provider reported $3.84 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.45 by $0.39. CIGNA had a net margin of 6.15% and a return on equity of 23.31%. The firm had revenue of $11.45 billion during the quarter, compared to analyst estimates of $11.19 billion. During the same quarter in the prior year, the business posted $2.83 earnings per share. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. Equities analysts predict that CIGNA will post 14.35 EPS for the current fiscal year.

In other news, insider Jason D. Sadler sold 21,189 shares of the firm’s stock in a transaction that occurred on Friday, November 2nd. The shares were sold at an average price of $212.99, for a total transaction of $4,513,045.11. Following the completion of the sale, the insider now owns 41,966 shares of the company’s stock, valued at $8,938,338.34. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Michael W. Triplett sold 2,825 shares of the firm’s stock in a transaction that occurred on Monday, November 5th. The stock was sold at an average price of $214.25, for a total transaction of $605,256.25. Following the sale, the insider now directly owns 23,871 shares of the company’s stock, valued at approximately $5,114,361.75. The disclosure for this sale can be found here. Company insiders own 1.10% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc increased its holdings in shares of CIGNA by 1.5% in the third quarter. Vanguard Group Inc now owns 17,800,567 shares of the health services provider’s stock valued at $3,706,967,000 after purchasing an additional 260,042 shares in the last quarter. FMR LLC increased its holdings in shares of CIGNA by 18.6% in the third quarter. FMR LLC now owns 8,970,440 shares of the health services provider’s stock valued at $1,868,093,000 after purchasing an additional 1,409,335 shares in the last quarter. Capital World Investors increased its holdings in shares of CIGNA by 172.7% in the third quarter. Capital World Investors now owns 5,464,526 shares of the health services provider’s stock valued at $1,137,988,000 after purchasing an additional 3,460,726 shares in the last quarter. Veritas Asset Management LLP increased its holdings in shares of CIGNA by 5.1% in the third quarter. Veritas Asset Management LLP now owns 4,648,900 shares of the health services provider’s stock valued at $968,133,000 after purchasing an additional 226,700 shares in the last quarter. Finally, Sanders Capital LLC increased its holdings in shares of CIGNA by 4.6% in the third quarter. Sanders Capital LLC now owns 3,490,224 shares of the health services provider’s stock valued at $797,672,000 after purchasing an additional 151,971 shares in the last quarter. 93.47% of the stock is owned by institutional investors.

About CIGNA

Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. It operates through Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations segments. The Global Health Care segment offers medical, dental, behavioral health, vision, and prescription drug benefit plans, as well as health advocacy programs, and other products and services to insured and self-insured customers.

Featured Story: What does the Dow Jones Industrial Average (DJIA) measure?

Analyst Recommendations for CIGNA (NYSE:CI)

Receive News & Ratings for CIGNA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CIGNA and related companies with MarketBeat.com's FREE daily email newsletter.